Incidence of septic arthritis in patients with ankylosing spondylitis and seropositive rheumatoid arthritis following TNF inhibitor therapy
Authors' conclusion
TNF inhibitors increase the incidence of SA, specifically in patients with SPRA, but not AS.
Study context
- Population
- Incident cases of AS and seropositive RA (SPRA), South Korean Health Insurance Review and Assessment Service database, 2010–2020analysed
- Participants
- 145,129 cases
- Exposure
- TNFi use vs no TNFi use in AS and SPRA
- Outcome
- Incidence of septic arthritis (diagnostic code M00 and hospital admission)
Methodological detailsnationwide claims database, Cox proportional hazards analysis
- Nationwide claims database
- Cox proportional hazards analysis
Main finding
As reported in the abstract
Septic arthritis during follow-up
Patients who developed septic arthritis (SA), overall
1170
0.8%
Observational data: associations, not effects.
Further findings
Predictors of SA
- Overall: older age, male sex, SPRA diagnosis, hypertension, diabetes mellitus (DM), chronic pulmonary disease increased SA incidence
- AS: only age and renal disease were predictors of SA
- SPRA: age, hypertension, DM and chronic pulmonary disease were associated with SA
Timing of SA after TNFi start
- SA incidence prominent after the first year of commencing TNFi, for both AS and SPRA
Original publication
Incidence of septic arthritis in patients with ankylosing spondylitis and seropositive rheumatoid arthritis following TNF inhibitor therapy. Rheumatology (Oxford). Published 23 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →